Inhibiting glucocorticoid release, NF-κB nuclear transcription, NLRP3 inflammasome activation and restoring microglial homeostasis in the hippocampus are novel strategies for the development of effective treatments for the management of depression in humans. Here, NLRP3 is linked to major depressive disorder.